6 research outputs found
Chiral Surfactant-Type Catalyst: Enantioselective Reduction of Long-Chain Aliphatic Ketoesters in Water
A series of amphiphilic ligands were
designed and synthesized.
The rhodium complexes with the ligands were applied to the asymmetric
transfer hydrogenation of broad range of long-chained aliphatic ketoesters
in neat water. Quantitative conversion and excellent enantioselectivity
(up to 99% ee) was observed for α-, β-, γ-, δ-
and ε-ketoesters as well as for α- and β-acyloxyketone
using chiral surfactant-type catalyst <b>2</b>. The CH/π
interaction and the strong hydrophobic interaction of long aliphatic
chains between the catalyst and the substrate in the metallomicelle
core played a key role in the catalytic transition state. Synergistic
effects between the metal-catalyzed site and the hydrophobic microenvironment
of the core in the micelle contributed to high stereoselectivity
Nanocrystals Slow-Releasing Ropivacaine and Doxorubicin to Synergistically Suppress Tumor Recurrence and Relieve Postoperative Pain
Although surgical resection provides a straightforward
and effective
treatment for most malignant solid tumors, tumor recurrence and acute
postoperative pain continue to be two big problems associated with
this treatment. To resolve these problems, a nanocrystal composite
slow-releasing ropivacaine and doxorubicin was fabricated in this
study. Briefly, a self-assembling peptide was used to form nanoparticle
complexes with the two drugs, based on which homogeneous nanocrystals
were obtained by adjusting the pH. In cultured human melanoma cells,
the nanocrystals exhibited improved antitumor activity due to a synergistic
effect and enhanced cellular uptake of the two drugs. On the other
hand, the nanocrystals could slowly release ropivacaine in
vitro and in vivo, generating long-acting
analgesia on the rat sciatic nerve block model and incisional pain
model. On a nude mouse tumor resection model, the nanocrystals simultaneously
suppressed the recurrence of solid tumor and relieved postoperative
pain, indicating a potential postoperative treatment for tumor resection
patients. This nanocrystal system also suggested a promising and facile
strategy for developing multifunctional formulations combining different
drugs, which could achieve better therapeutic outcomes in a synergistic
and sustained manner
Nanocrystals Slow-Releasing Ropivacaine and Doxorubicin to Synergistically Suppress Tumor Recurrence and Relieve Postoperative Pain
Although surgical resection provides a straightforward
and effective
treatment for most malignant solid tumors, tumor recurrence and acute
postoperative pain continue to be two big problems associated with
this treatment. To resolve these problems, a nanocrystal composite
slow-releasing ropivacaine and doxorubicin was fabricated in this
study. Briefly, a self-assembling peptide was used to form nanoparticle
complexes with the two drugs, based on which homogeneous nanocrystals
were obtained by adjusting the pH. In cultured human melanoma cells,
the nanocrystals exhibited improved antitumor activity due to a synergistic
effect and enhanced cellular uptake of the two drugs. On the other
hand, the nanocrystals could slowly release ropivacaine in
vitro and in vivo, generating long-acting
analgesia on the rat sciatic nerve block model and incisional pain
model. On a nude mouse tumor resection model, the nanocrystals simultaneously
suppressed the recurrence of solid tumor and relieved postoperative
pain, indicating a potential postoperative treatment for tumor resection
patients. This nanocrystal system also suggested a promising and facile
strategy for developing multifunctional formulations combining different
drugs, which could achieve better therapeutic outcomes in a synergistic
and sustained manner
Nanocrystals Slow-Releasing Ropivacaine and Doxorubicin to Synergistically Suppress Tumor Recurrence and Relieve Postoperative Pain
Although surgical resection provides a straightforward
and effective
treatment for most malignant solid tumors, tumor recurrence and acute
postoperative pain continue to be two big problems associated with
this treatment. To resolve these problems, a nanocrystal composite
slow-releasing ropivacaine and doxorubicin was fabricated in this
study. Briefly, a self-assembling peptide was used to form nanoparticle
complexes with the two drugs, based on which homogeneous nanocrystals
were obtained by adjusting the pH. In cultured human melanoma cells,
the nanocrystals exhibited improved antitumor activity due to a synergistic
effect and enhanced cellular uptake of the two drugs. On the other
hand, the nanocrystals could slowly release ropivacaine in
vitro and in vivo, generating long-acting
analgesia on the rat sciatic nerve block model and incisional pain
model. On a nude mouse tumor resection model, the nanocrystals simultaneously
suppressed the recurrence of solid tumor and relieved postoperative
pain, indicating a potential postoperative treatment for tumor resection
patients. This nanocrystal system also suggested a promising and facile
strategy for developing multifunctional formulations combining different
drugs, which could achieve better therapeutic outcomes in a synergistic
and sustained manner
Nanocrystals Slow-Releasing Ropivacaine and Doxorubicin to Synergistically Suppress Tumor Recurrence and Relieve Postoperative Pain
Although surgical resection provides a straightforward
and effective
treatment for most malignant solid tumors, tumor recurrence and acute
postoperative pain continue to be two big problems associated with
this treatment. To resolve these problems, a nanocrystal composite
slow-releasing ropivacaine and doxorubicin was fabricated in this
study. Briefly, a self-assembling peptide was used to form nanoparticle
complexes with the two drugs, based on which homogeneous nanocrystals
were obtained by adjusting the pH. In cultured human melanoma cells,
the nanocrystals exhibited improved antitumor activity due to a synergistic
effect and enhanced cellular uptake of the two drugs. On the other
hand, the nanocrystals could slowly release ropivacaine in
vitro and in vivo, generating long-acting
analgesia on the rat sciatic nerve block model and incisional pain
model. On a nude mouse tumor resection model, the nanocrystals simultaneously
suppressed the recurrence of solid tumor and relieved postoperative
pain, indicating a potential postoperative treatment for tumor resection
patients. This nanocrystal system also suggested a promising and facile
strategy for developing multifunctional formulations combining different
drugs, which could achieve better therapeutic outcomes in a synergistic
and sustained manner
Nanocrystals Slow-Releasing Ropivacaine and Doxorubicin to Synergistically Suppress Tumor Recurrence and Relieve Postoperative Pain
Although surgical resection provides a straightforward
and effective
treatment for most malignant solid tumors, tumor recurrence and acute
postoperative pain continue to be two big problems associated with
this treatment. To resolve these problems, a nanocrystal composite
slow-releasing ropivacaine and doxorubicin was fabricated in this
study. Briefly, a self-assembling peptide was used to form nanoparticle
complexes with the two drugs, based on which homogeneous nanocrystals
were obtained by adjusting the pH. In cultured human melanoma cells,
the nanocrystals exhibited improved antitumor activity due to a synergistic
effect and enhanced cellular uptake of the two drugs. On the other
hand, the nanocrystals could slowly release ropivacaine in
vitro and in vivo, generating long-acting
analgesia on the rat sciatic nerve block model and incisional pain
model. On a nude mouse tumor resection model, the nanocrystals simultaneously
suppressed the recurrence of solid tumor and relieved postoperative
pain, indicating a potential postoperative treatment for tumor resection
patients. This nanocrystal system also suggested a promising and facile
strategy for developing multifunctional formulations combining different
drugs, which could achieve better therapeutic outcomes in a synergistic
and sustained manner